Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00446199 · ClinicalTrials.gov registry record · Phase 3
Low-dose Hormone Therapy for Relief of Vasomotor Symptoms
A Phase 3 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 3
- Development phase
- 735
- Enrollment target
NCT00446199 is a Phase 3 study that has completed, run by Bayer. The registered enrollment target is 735 participants.
The verdict
NCT00446199, a Phase 3 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 735 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the lowest effective dose of the study drug for the relief of moderate to severe vasomotor symptoms in postmenopausal women for 12 weeks.
Interventions
- DRUG Placebo
- DRUG 0.25mg DRSP / 0.5mg E2 (BAY86-4891)
- DRUG 0.5mg DRSP / 0.5mg E2 (BAY86-4891)
- DRUG Estradiol (E2 0.3mg)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 735 participants |
| Start Date | 2007-03 |
| Est. Completion | 2008-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00446199
The ClinicalTrials.gov registry entry for NCT00446199 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 735 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT00446199 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00446199 about?
NCT00446199 is a clinical study titled "Low-dose Hormone Therapy for Relief of Vasomotor Symptoms". The purpose of this study is to determine the lowest effective dose of the study drug for the relief of moderate to severe vasomotor symptoms in postmenopausal women for 12 weeks.
What is the current status of trial NCT00446199?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 735 participants. The study started on 2007-03. Estimated completion is 2008-11.
What interventions are being tested in trial NCT00446199?
The interventions under investigation include: Placebo (DRUG), 0.25mg DRSP / 0.5mg E2 (BAY86-4891) (DRUG), 0.5mg DRSP / 0.5mg E2 (BAY86-4891) (DRUG), Estradiol (E2 0.3mg) (DRUG).
Who is sponsoring clinical trial NCT00446199?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.